EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An analysis of AURKB 's prognostic and immunological roles across various cancers

Jun Li iD, Cui Cheng iD, Jiajun Zhang

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Jun Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Aurora Kinase B, DNA Methylation, Promoter Regions, Genetic, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bengbu Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aurora kinase B (AURKB), an essential regulator in the process of mitosis, has been revealed through various studies to have a significant role in cancer development and progression. However, the specific mechanisms remain poorly understood. This study, therefore, seeks to elucidate the multifaceted role of AURKB in diverse cancer types. This study utilized bioinformatics techniques to examine the transcript, protein, promoter methylation and mutation levels of AURKB. The study further analysed associations between AURKB and factors such as prognosis, pathological stage, biological function, immune infiltration, tumour mutational burden (TMB) and microsatellite instability (MSI). In addition, immunohistochemical staining data of 50 cases of renal clear cell carcinoma and its adjacent normal tissues were collected to verify the difference in protein expression of AURKB in the two tissues. The results show that AURKB is highly expressed in most cancers, and the protein level of AURKB and the methylation level of its promoter vary among cancer types. Survival analysis showed that AURKB was associated with overall survival in 12 cancer types and progression‐free survival in 11 cancer types. Elevated levels of AURKB were detected in the advanced stages of 10 different cancers. AURKB has a potential impact on cancer progression through its effects on cell cycle regulation as well as inflammatory and immune‐related pathways. We observed a strong association between AURKB and immune cell infiltration, immunomodulatory factors, TMB and MSI. Importantly, we confirmed that the AURKB protein is highly expressed in kidney renal clear cell carcinoma (KIRC). Our study reveals that AURKB may be a potential biomarker for pan‐cancer and KIRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aurora Kinase BDNA MethylationPromoter Regions, GeneticNeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansPrognosisMicrosatellite InstabilityMutationFemaleComputational Biology

Stichwörter der Autor:innen

biomarkercell cycleimmune infiltrationimmunotherapykidney renal clear cell carcinomapan‐cancer

Substanzen

Aurora Kinase BBiomarkers, TumorAURKB protein, human

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • Department of Gynaecological Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.

ORCID-Profile: Jun Li, Cui Cheng

Förderung

  • Bengbu Medical College

Zitieren

APA

Li, J., Cheng, C., & Zhang, J. (2024). An analysis of AURKB 's prognostic and immunological roles across various cancers. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18475

Vancouver

Li J, Cheng C, Zhang J. An analysis of AURKB 's prognostic and immunological roles across various cancers. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18475

BibTeX
@article{Li2024,
  author = {Li, Jun and Cheng, Cui and Zhang, Jiajun},
  title = {An analysis of AURKB 's prognostic and immunological roles across various cancers},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18475}
}
Kostenlos starten →